First Data for Moderna COVID-19 Vaccine Show it Spurs an Immune Response

July 16, 2020 by Christen Aldrich

Filed under COVID-19 for Employers, COVID-19 for the Workforce

Last modified July 17, 2020

According to the first published data by The New England Journal of Medicine, Moderna’s COVID-19 vaccine led patients to produce antibodies that can neutralize the novel coronavirus that causes the disease, though it caused minor side effects in many patients.

“It certainly is a good beginning,” said Betty Diamond, director at the Feinstein Institutes for Medical Research, who was not involved in the trial. “There are certainly lots of things we don’t know yet right now.”

The study, which was run by the National Institutes of Health, showed that volunteers who received the vaccine made more neutralizing antibodies than have been seen in most patients who have recovered from COVID-19. But a second injection, four weeks after the first, was required before the vaccine produced a dramatic immune response.

Share this

Related Articles

                                Leave a Comment